chr7-55161509-C-T

Variant summary

Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2

The NM_005228.5(EGFR):​c.1509C>T​(p.Gly503=) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0113 in 1,614,058 control chromosomes in the GnomAD database, including 114 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).

Frequency

Genomes: 𝑓 0.0084 ( 12 hom., cov: 34)
Exomes 𝑓: 0.012 ( 102 hom. )

Consequence

EGFR
NM_005228.5 synonymous

Scores

2

Clinical Significance

Benign/Likely benign criteria provided, multiple submitters, no conflicts B:6

Conservation

PhyloP100: -0.215
Variant links:
Genes affected
EGFR (HGNC:3236): (epidermal growth factor receptor) The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor, thus inducing receptor dimerization and tyrosine autophosphorylation leading to cell proliferation. Mutations in this gene are associated with lung cancer. EGFR is a component of the cytokine storm which contributes to a severe form of Coronavirus Disease 2019 (COVID-19) resulting from infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). [provided by RefSeq, Jul 2020]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Benign. Variant got -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.73).
BP6
Variant 7-55161509-C-T is Benign according to our data. Variant chr7-55161509-C-T is described in ClinVar as [Likely_benign]. Clinvar id is 695386.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr7-55161509-C-T is described in Lovd as [Benign].
BP7
Synonymous conserved (PhyloP=-0.215 with no splicing effect.
BS1
Variant frequency is greater than expected in population nfe. gnomad4 allele frequency = 0.00839 (1278/152382) while in subpopulation NFE AF= 0.0129 (879/68044). AF 95% confidence interval is 0.0122. There are 12 homozygotes in gnomad4. There are 600 alleles in male gnomad4 subpopulation. Median coverage is 34. This position pass quality control queck.
BS2
High Homozygotes in GnomAd4 at 12 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
EGFRNM_005228.5 linkuse as main transcriptc.1509C>T p.Gly503= synonymous_variant 13/28 ENST00000275493.7

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
EGFRENST00000275493.7 linkuse as main transcriptc.1509C>T p.Gly503= synonymous_variant 13/281 NM_005228.5 P1P00533-1

Frequencies

GnomAD3 genomes
AF:
0.00839
AC:
1278
AN:
152264
Hom.:
12
Cov.:
34
show subpopulations
Gnomad AFR
AF:
0.00222
Gnomad AMI
AF:
0.0110
Gnomad AMR
AF:
0.00765
Gnomad ASJ
AF:
0.00173
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00145
Gnomad FIN
AF:
0.0136
Gnomad MID
AF:
0.00633
Gnomad NFE
AF:
0.0129
Gnomad OTH
AF:
0.00956
GnomAD3 exomes
AF:
0.00758
AC:
1902
AN:
250984
Hom.:
12
AF XY:
0.00783
AC XY:
1063
AN XY:
135674
show subpopulations
Gnomad AFR exome
AF:
0.00135
Gnomad AMR exome
AF:
0.00460
Gnomad ASJ exome
AF:
0.00258
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00219
Gnomad FIN exome
AF:
0.0140
Gnomad NFE exome
AF:
0.0111
Gnomad OTH exome
AF:
0.0106
GnomAD4 exome
AF:
0.0116
AC:
17009
AN:
1461676
Hom.:
102
Cov.:
31
AF XY:
0.0114
AC XY:
8300
AN XY:
727170
show subpopulations
Gnomad4 AFR exome
AF:
0.00140
Gnomad4 AMR exome
AF:
0.00476
Gnomad4 ASJ exome
AF:
0.00214
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00195
Gnomad4 FIN exome
AF:
0.0141
Gnomad4 NFE exome
AF:
0.0136
Gnomad4 OTH exome
AF:
0.0103
GnomAD4 genome
AF:
0.00839
AC:
1278
AN:
152382
Hom.:
12
Cov.:
34
AF XY:
0.00805
AC XY:
600
AN XY:
74512
show subpopulations
Gnomad4 AFR
AF:
0.00221
Gnomad4 AMR
AF:
0.00764
Gnomad4 ASJ
AF:
0.00173
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00145
Gnomad4 FIN
AF:
0.0136
Gnomad4 NFE
AF:
0.0129
Gnomad4 OTH
AF:
0.00946
Alfa
AF:
0.0101
Hom.:
7
Bravo
AF:
0.00749
Asia WGS
AF:
0.00231
AC:
8
AN:
3478
EpiCase
AF:
0.00998
EpiControl
AF:
0.0108

ClinVar

Significance: Benign/Likely benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
Likely benign, criteria provided, single submitterclinical testingGeneDxSep 15, 2020- -
Benign, criteria provided, single submitterclinical testingCeGaT Center for Human Genetics TuebingenJun 01, 2024EGFR: BP4, BP7, BS1, BS2 -
Benign, criteria provided, single submitterclinical testingARUP Laboratories, Molecular Genetics and Genomics, ARUP LaboratoriesOct 16, 2023- -
not specified Benign:2
Benign, no assertion criteria providedclinical testingDepartment of Pathology and Laboratory Medicine, Sinai Health System-The EGFR p.Gly503Gly variant was identified in the literature in a Korean cohort of 27 lung cancer cases (frequency: 0.41) and 27 controls (frequency: 0.41) (Choi_2007_PMID:12956637). The variant was also identified in a case report of an individual with suspected plasma cell neoplasm (Peterson_2019_PMID:31320253). The variant was identified in dbSNP (ID: rs17336800), ClinVar (classified as benign by Invitae) and LOVD 3.0, but was not identified in Cosmic. The variant was identified in control databases in 2092 of 267912 chromosomes (14 homozygous) at a frequency of 0.007809 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: European (Finnish) in 348 of 24930 chromosomes (freq: 0.01396), European (non-Finnish) in 1370 of 117988 chromosomes (freq: 0.01161), Other in 75 of 6696 chromosomes (freq: 0.0112), Latino in 163 of 35096 chromosomes (freq: 0.004644), Ashkenazi Jewish in 24 of 9852 chromosomes (freq: 0.002436), South Asian in 67 of 30502 chromosomes (freq: 0.002197) and African in 45 of 23606 chromosomes (freq: 0.001906), but was not observed in the East Asian population. The p.Gly503Gly variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site. However, three of four in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) predict a greater than 10% difference in splicing and the creation of a new 5' splice site. However, this has not been confirmed by RNA analysis and is not predictive enough to assume pathogenicity. In summary, based on the above information this variant meets our laboratory's criteria to be classified as benign. -
Benign, criteria provided, single submitterclinical testingGenetic Services Laboratory, University of ChicagoJul 26, 2021- -
EGFR-related lung cancer Benign:1
Benign, criteria provided, single submitterclinical testingInvitaeFeb 01, 2024- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.73
CADD
Benign
2.6
DANN
Benign
0.44
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.11
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs17336800; hg19: chr7-55229202; COSMIC: COSV99296679; COSMIC: COSV99296679; API